Atlas market file · Equity · United States
ProQR Therapeutics N.V.PRQR
- Last close
- 1.875
- Change
- -1.32%
- 96-bar range
- 1.35 – 2.15
- As of
- 7 Aug 2026
ProQR Therapeutics N.V. is a pharmaceutical preparations issuer listed as PRQR on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
PRQR
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-12.38% over the window).
Source rail: Yahoo Finance chart API (PRQR). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for PRQR. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
PRQR public profile
Pharmaceutical preparations issuer. ProQR Therapeutics N.V. is connected to current market context, cited company sources and its retained research file.
ProQR Therapeutics N.V. trades as PRQR on NASDAQ. ProQR Therapeutics N.V. (PRQR) has a latest verified close of 1.875, down 1.32%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files PRQR under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for ProQR Therapeutics N.V. today
ProQR Therapeutics N.V. (PRQR) has made a significant stride in the biotech arena with the announcement of positive Phase 1 target engagement data for AX-0810, marking the first clinical validation of its Axiomer RNA editing platform. This milestone is akin to a scientist finally proving that their experimental concoction has tangible effects, a rare and welcome occurrence in the often tumultuous world of biotech (source: ProQR Therapeutics, https://www.proqr.com/press-releases/proqr-announces-positive-phase-1-target-engagement-data-for-ax-0810-establishing-first-clinical-validation-of-the-axiomer-rna-editing-platform).
The company, based in the Netherlands, specializes in discovering and developing unique RNA-based therapies for severe genetic disorders. ProQR's Axiomer platform technology enables the specific editing of single nucleotides in RNA, a cutting-edge approach that has attracted the attention of industry giants like Eli Lilly, with whom ProQR has partnered to leverage this innovative technology (source: ProQR Therapeutics, https://www.proqr.com/community-stories-and-news/exploring-why-companies-partner-their-technology).
Financially, ProQR's first quarter 2026 results paint a picture of a company deeply invested in its research and development efforts. While the company has yet to generate revenue, its operating expenses are substantial, reflecting the high costs associated with clinical-stage biotech firms. The financials serve as a stark reminder of the challenges faced by companies in this sector, where scientific breakthroughs do not always translate into immediate financial gains (source: ProQR Therapeutics, https://www.proqr.com/press-releases/proqr-announces-first-quarter-2026-operating-and-financial-results).
For those interested in the company's scientific advancements, ProQR has a robust pipeline with multiple upcoming presentations at scientific conferences. These events provide a platform for the company to showcase the breadth of its Axiomer RNA Editing Platform, further solidifying its position as a leader in RNA-based therapies (source: ProQR Therapeutics, https://www.proqr.com/press-releases).
Sources & evidence · 5 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
PRQR technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on PRQR
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep PRQR research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
PRQR FAQ
What is ProQR Therapeutics N.V. (PRQR)?ProQR Therapeutics N.V. (PRQR) has a latest verified close of 1.875, down 1.32%, dated 7 Aug 2026. Use this page to check the price chart, company context,...
ProQR Therapeutics N.V. (PRQR) has a latest verified close of 1.875, down 1.32%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for PRQR?ProQR Therapeutics N.V. (PRQR) has a latest verified close of 1.875, down 1.32%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources,...
ProQR Therapeutics N.V. (PRQR) has a latest verified close of 1.875, down 1.32%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files PRQR under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the PRQR page updated?The PRQR public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The PRQR public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for PRQR?The PRQR file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:PRQR. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The PRQR file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:PRQR. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on PRQR?Yes. The workstation can open PRQR, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open PRQR, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this PRQR page investment advice?No. The PRQR page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The PRQR page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →